Personalizing KRAS-Mutant Allele-Specific Therapies.,Cancer Discovery

当前位置： X-MOL 学术 › Cancer Discov. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Personalizing KRAS-Mutant Allele-Specific Therapies.
Cancer Discovery ( IF 29.7 ) Pub Date : 2020-01-01 , DOI: 10.1158/2159-8290.cd-19-1261
Chiara Falcomatà _{1,

2} , Günter Schneider _{1,

3} , Dieter Saur _{1,

2,

3}

Affiliation

KRAS G12R mutations occur almost exclusively in pancreatic ductal adenocarcinoma. The results of a study that reveals specific differences in KRAS downstream signaling and metabolic rewiring of pancreatic cancer cells harboring KRAS G12R mutations promise to improve our possibilities to better stratify patients for individualized therapies.See related article by Hobbs et al., p. 104.

中文翻译：